D-0097-2021 Class II Terminated

Recalled by Ascent Pharmaceuticals, Inc. — Central Islip, NY

FDA drug recall D-0097-2021 was initiated by Ascent Pharmaceuticals, Inc. on Oct 26, 2020 and is designated Class II. Reason for recall: Presence of Foreign Tablet/Capsule: One bottle of Hydrocodone Bitartrate and Acetaminophen Tablets USP 10mg/325 mg contains one Losartan Potassium Tablets, USP 100 mg. The recall status is terminated (terminated Feb 17, 2023). Affected quantity: 9768 Bottles.

Recall details

Product Type
Drugs
Report Date
Nov 25, 2020
Initiation Date
Oct 26, 2020
Termination Date
Feb 17, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
9768 Bottles

Product description

Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/325mg 100-count bottles, Rx Only, Manufactured for : Camber Pharmaceuticals, Inc. Piscataway, NJ 08854, Manufactured by: Ascent Pharmaceuticals, Inc. Central Islip, NY 11722, NDC 31722-943-01

Reason for recall

Presence of Foreign Tablet/Capsule: One bottle of Hydrocodone Bitartrate and Acetaminophen Tablets USP 10mg/325 mg contains one Losartan Potassium Tablets, USP 100 mg.

Distribution pattern

Nationwide within the United States

Code information

Lot #: 20070518, Exp. Date June 2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0097-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0097-2021. Report a data issue: hello@regdatalab.com.